<p>Section 1: HEPATITIS: ADVANCES IN CLINICAL EVALUATION <br>1. Noninvasive assessment of liver disease severity: image-related<br>2. Noninvasive assessments of liver disease severity based on biomarkers<br>3. Conventional liver imaging in hepatitis<br>4. Nutrition in liver disease</p> <p>Section II: VIRAL HEPATITIS <br>5. Antivirals against hepatitis viruses: basic mechanisms<br>6. Hepatitis A and hepatitis E<br>7. Hepatitis B: epidemiology, natural history, and diagnosis<br>8. Hepatitis B: treatment<br>9. Hepatitis C: epidemiology, natural history, and diagnosis<br>10. Hepatitis C: treatment<br>11. Hepatitis D</p> <p>Section III: HEPATITIS: METABOLIC, ALCOHOL, AND DRUG INDUCED<br>12. Metabolic-associated fatty liver disease: epidemiology, natural history and diagnosis, current paradigm and definitions for MAFLD<br>13. Metabolic-associated fatty liver disease: pharmacological management<br>14. Non-pharmacological treatment approach in patients with metabolic dysfunctionassociated liver disease<br>15. Alcoholic hepatitis<br>16. Drug-induced liver injury caused by conventional drugs, using cases based on the Roussel Uclaf causality assessment method<br>17. Introduction to drug-induced liver injury</p> <p>Section IV: HEPATITIS: CHOLESTATIC, GENETIC, AND AUTOIMMUNE CAUSES<br>18. Current paradigm and treatment options for autoimmune hepatitis<br>19. Hereditary hemochromatosis<br>20. Wilson disease<br>21. Alpha-1 antitrypsin deficiency</p> <p>Section V: HEPATITIS: INFECTIONS AND SYSTEMIC CAUSES<br>22. Hepatitis: infections and systemic causes<br>23. HIV: hepatic manifestations of HIV and antiretroviral therapy<br>24. Systemic non-infectious hepatitis<br>25. Concurrent HCV or fatty liver in patients with chronic hepatitis B virus infection</p> <p>Section VI: CHILDHOOD AND PREGNANCY<br>26. Hepatitis during childhood<br>27. Hepatitis during pregnancy</p> <p> <br></p>
